Source: Medisafe
A few months after Medisafe revealed that it had developed a platform for pharma companies to gain big data analysis on medication adherence patterns using data from its app, the company has developed an infographic with snapshots of medication adherence insights. Although much of the information reflects medication adherence across its user base, the infographic that I’ve clipped into slides illustrates some interesting insights Medisafe has developed about its customer base through their data.
There’s an expression that my early riser of a dad used to never tire of saying — the morning hours are the golden ones — and that seems to hold true for medication adherence as well. Medisafe’s data showed that for its user base, 5am – 9am is when adherence is strongest. Mid-afternoon is the lowest point when adherence slackens to 73 percent.
Source: Medisafe
Chronic conditions can be a particularly vexing area when it comes to the challenge of improving adherence and Medisafe’s chart (above) effectively visualizes that struggle for diabetes patients. The reasons vary from person to person, but the daily challenge to stay within healthy parameters for an individual’s blood glucose levels can be stressful and lead to depression, undermining how well these patients manage their condition.
MobiHealthNews earlier this month reported that Medisafe Executive Vice President of Marketing and Business Development Jon Michael announced at the Partners Connected Healthcare Symposium that the company would finally roll out to the mass market its connected pill caps (iCap) and pillbox (iSort) this week. The move comes six months after the digital health business offered up these products for pre-sale.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
